title: Idarucizumab for Dabigatran Reversal Guideline.
authors.affiliation: From the Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT.
authors.forename: David P
authors.initials: DP
authors.lastname: Reardon
authors.forename: Kent
authors.initials: K
authors.lastname: Owusu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D003029:Coagulants / Q000008:administration & dosage; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects*; D016903:Drug Monitoring / Q000379:methods; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; D003029:Coagulants; C000594745:idarucizumab; D000069604:Dabigatran